Vermillion Expects $2M Payment from Bio-Rad Following Patent Re-Issue

Nov 05, 2007

NEW YORK (GenomeWeb News) – The US Patent and Trademark Office has re-issued a patent covering SELDI mass spec-related technology to Vermillion, formerly called Ciphergen, that entitles the diagnostics developer to a $2 million payment from Bio-Rad Laboratories, Vermillion said today.

Bio-Rad agreed to the payment when it bought Vermillion’s proteomics tools business a year ago for $20 million in cash and a $3 million investment.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

Persistent Gap

Researchers examine the gap in funding between researchers and research institutions, ScienceInsider reports

Puppies' Past

By sequencing two ancient dog genomes, researchers from the US and Germany suggest that dogs were domesticated in a single event, the Washington Post reports.

This Week in Genome Research

In Genome Research this week: population dynamics of E. coli infection, lncRNA expression changes in macaque aging, and more.

Sourdough-ome

Researchers are using sourdough starter to get a glimpse into the factors and processes that influence the microbiome, NPR reports.

Main menu